Orchard Therapeutics PLC represents values of innovation, collaboration, and patient-focused care. Their corporate philosophy is centered around developing transformative gene therapies for rare diseases. With a commitment to advancing precision medicine, Orchard Therapeutics PLC aims to improve the lives of patients through the development and commercialization of innovative treatments. Their dedicated team of experts, cutting-edge research, and strategic partnerships drive their mission to address critical unmet medical needs. Orchard Therapeutics PLC is dedicated to delivering hope and long-term solutions to patients and their families, making a positive impact on the healthcare industry.

Orchard Therapeutics PLC is primarily present in several countries and regions. The company's presence extends to the United States, the United Kingdom, and the European Union. With its headquarters in London, Orchard Therapeutics PLC has established a strong global footprint within the pharmaceutical industry. By focusing on gene therapies and developing innovative treatment options, Orchard Therapeutics PLC offers hope to patients worldwide. As a trusted name in the field, Orchard Therapeutics PLC continues to expand its reach and impact, striving to improve the lives of individuals affected by serious rare diseases.

Orchard Therapeutics PLC has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on October 31, 2018, raising approximately $200 million. This allowed Orchard Therapeutics to expand its operations and further progress its pipeline of innovative gene therapies. Additionally, the company obtained Breakthrough Therapy Designation from the U.S. FDA for its ex vivo autologous hematopoietic stem cell gene therapy in 2018. Orchard Therapeutics also initiated multiple clinical trials for various rare diseases, demonstrating the efficacy and safety of their therapies. Moreover, the company has entered strategic collaborations with renowned organizations like GSK and UCLA for further advancements in its gene therapy research and development. Orchard Therapeutics PLC continues to achieve remarkable milestones on its mission to transform the lives of patients with serious genetic diseases.

Orchard Therapeutics PLC is a renowned biopharmaceutical company specializing in gene therapies for rare diseases. Founded in 2015, Orchard Therapeutics focuses on developing innovative treatments using ex-vivo autologous hematopoietic stem cell gene therapy. With a mission to transform the lives of patients with severe genetic disorders, Orchard Therapeutics aims to provide long-lasting and potentially curative solutions. The company has a comprehensive portfolio of therapies in different stages of development, targeting disorders like inherited immunodeficiencies, metabolic disorders, and more. Orchard Therapeutics brings together cutting-edge science, experienced professionals, and strategic collaborations to drive advancements in the field of gene therapy and improve outcomes for patients worldwide.

The main competitors of Orchard Therapeutics PLC in the market include bluebird bio, CRISPR Therapeutics, and Novartis AG.

Orchard Therapeutics PLC primarily operates in the biotechnology and pharmaceutical industries.

The business model of Orchard Therapeutics PLC focuses on developing and commercializing gene therapies for the treatment of rare genetic diseases. The company utilizes ex-vivo gene therapy approaches, where a patient's own cells are genetically modified outside the body and then infused back into the patient. By leveraging this innovative technology, Orchard Therapeutics aims to provide long-term, potentially curative therapies to patients suffering from debilitating genetic disorders. With a strong emphasis on research and development, the company strives to address unmet medical needs and improve the lives of patients with rare diseases worldwide.

Poměr Orchard Therapeutics P/E je -6,13.

Koeficient Orchard Therapeutics tržních hodnot je 37,73.

AlleAktien kvalitní skóre pro Orchard Therapeutics je 3/10.

očekávané Orchard Therapeutics obrat je 56,64 mil. USD.

očekávané Orchard Therapeutics zisk je -348,58 mil. USD.

Orchard Therapeutics PLC is a biopharmaceutical company based in the UK that specializes in the development and commercialization of gene therapies for rare diseases. The company utilizes a technology known as ex-vivo gene therapy, where the target gene is modified in the laboratory and then administered to the patients. The company operates in two business segments: research and development, and product commercialization. Orchard Therapeutics focuses on rare immunodeficiency diseases and utilizes their ex-vivo gene therapy technology to treat a variety of genetic diseases. In the research and development field, the company works on developing new gene therapy products for various rare diseases. This includes identifying target genes as well as developing the gene therapy itself. Orchard Therapeutics evaluates both their own technologies and technologies from partners. Currently, Orchard Therapeutics offers a gene therapy product called Strimvelis, which is used to treat ADA-SCID, a rare form of immunodeficiency. Strimvelis is the first gene therapy to receive conditional approval from the European Union. Additionally, the company plans to develop more gene therapy products for rare diseases. Orchard Therapeutics has already initiated clinical trials for their gene therapy products for Wiskott-Aldrich syndrome, metachromatic leukodystrophy, and X-linked adrenoleukodystrophy. Orchard Therapeutics works closely with regulatory authorities to ensure that their gene therapy products meet the highest standards of safety and efficacy. The company markets its products directly or through distribution partners to patients affected by rare diseases. To meet the demand for gene therapy products for rare diseases, the company has acquired a manufacturing facility for gene therapy products in California, USA. Orchard Therapeutics has also formed partnerships with other biotech companies to further develop their technology and products. The collaboration with GSK to develop a gene therapy for adrenoleukodystrophy has the potential to expand Orchard Therapeutics' portfolio. Overall, Orchard Therapeutics has a promising future in the gene therapy industry. With their ex-vivo gene therapy technology and ability to develop gene therapy products for a variety of rare diseases, the company is well positioned to improve the lives of patients with rare diseases.

Orchard Therapeutics vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Orchard Therapeutics momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Orchard Therapeutics je US68570P1012.

WKN společnosti Orchard Therapeutics je A2N8KD.

Ticker společnosti Orchard Therapeutics je ORTX.

Během posledních 12 měsíců vyplatila společnost Orchard Therapeutics dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Orchard Therapeutics vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Orchard Therapeutics aktuálně činí .

Orchard Therapeutics vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Orchard Therapeutics vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Orchard Therapeutics je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Orchard Therapeutics ve výši 0 USD, zaznamenané 18. 7. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 18. 7. 2024.

Poslední dividendy byly vyplaceny dne 18. 7. 2024.

V roce 2023 společností Orchard Therapeutics bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Orchard Therapeutics jsou vypláceny v USD.